Newsfile Corp
23 May 2026, 15:53 UTC · 1h ago
Source · https://www.newsfilecorp.com/release/298423/IBRX-SHAREHOLDER-ACTION-REMINDER-Faruqi-Faruqi-LLP-Reminds-ImmunityBio-IBRX-Investors-of-Securities-Class-Action-Deadline-on-May-26-2026
Read source
Search tags
Story key points
3 claims · impact-rated
A federal securities class action lawsuit has been filed against ImmunityBio (IBRX) alleging false and misleading statements regarding the capabilities of its drug, Anktiva. — Allegations of corporate fraud and misleading claims about a primary product typically increase risk profiles and can lead to significant legal liabilities.
-0.60The lawsuit claims that CEO Patrick Soon-Shiong materially overstated the capabilities of Anktiva, affecting the company's business prospects. — Direct allegations against key executives regarding product efficacy undermine investor confidence in leadership and the company's pipeline.
-0.40ImmunityBio's stock price fell 12.13% on January 23, 2026, following the release of updated Phase 2 clinical results for a glioblastoma regimen where the primary endpoint had not yet been reached. — The stock already reacted negatively to the clinical data, but the lawsuit focuses on the communication surrounding these results.
-0.30Impact vectors
3 dimensions · 9 clusters
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Ticker attribution
Model heads
The company is facing a federal securities class action lawsuit alleging false and misleading statements regarding product capabilities.
The company is mentioned as the subject of a securities class action deadline reminder.
The company is mentioned as the subject of a securities class action deadline reminder.
No ticker relationship head found.
